Bortezomib

Small molecule

Also known as MLN341, LDP-341, PS-341

Approvedregulatory verdict

Evidence outlook

Approved: Multiple Myeloma, Mantle Cell Lymphoma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (1)
EU
  • Velcade: progressive multiple myeloma (alone or with pegylated liposomal doxorubicin or dexamethasone); untreated multiple myeloma; mantle cell lymphoma
Product first approved 2004EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (101)
Mantle Cell Lymphoma
NCT01449344 · Prof. Dr. M. Dreyling (co-chairman)
2009-05-09 – 2018-12 · Mantle Cell Lymphoma
What this study did
Multiple Myeloma
NCT07903506 · Kite, A Gilead Company
2027-02 – 2042-03 · Newly Diagnosed Multiple Myeloma
What this study did
NCT07887672 · Kite, A Gilead Company
2027-01 – 2042-02 · Newly Diagnosed Multiple Myeloma
What this study did
NCT07624513 · Dana-Farber Cancer Institute
2026-08-31 – 2038-03-01 · Multiple Myeloma
What this study did
NCT06918002 · Intergroupe Francophone du Myelome
2025-07-09 – 2036-05 · Multiple Myeloma, Newly Diagnosed
What this study did
NCT07222761 · Regeneron Pharmaceuticals
2026-01-02 – 2034-08-23 · Relapsed and/or Refractory Multiple Myeloma (RRMM)
What this study did
NCT07285239 · PrECOG, LLC.
2026-12 – 2034-06 · Multiple Myeloma
What this study did
NCT07764978 · AstraZeneca
2026-06-26 – 2034-05-12 · Newly Diagnosed Multiple Myeloma
What this study did
NCT01863550 · ECOG-ACRIN Cancer Research Group
2013-12-06 – 2034-02-05 · Plasma Cell Myeloma
What this study did
NCT05572515 · Janssen Research & Development, LLC
2023-03-29 – 2031-08-31 · Multiple Myeloma
What this study did
NCT03710603 · Stichting European Myeloma Network
2018-12-14 – 2029-11 · Multiple Myeloma
What this study did
NCT05558319 · PETHEMA Foundation
2022-11-10 – 2029-04 · Newly Diagnosed Multiple Myeloma
What this study did
NCT03617731 · University of Heidelberg Medical Center
2018-10-18 – 2028-06 · Multiple Myeloma
What this study did
NCT04566328 · ECOG-ACRIN Cancer Research Group
2021-02-24 – 2027-12-31 · Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma
What this study did
NCT00572169 · University of Arkansas
2006-11 – 2027-08 · Multiple Myeloma
What this study did
NCT00644228 · National Cancer Institute (NCI)
2008-07-28 – 2027-06-10 · DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma
What this study did
NCT03729804 · University of Chicago
2019-05-07 – 2026-12-28 · Multiple Myeloma
What this study did
NCT03651128 · Celgene
2019-04-16 – 2026-04-13 · Multiple Myeloma
What this study did
NCT05804032 · University of Heidelberg Medical Center
2023-04-14 – 2026-01-30 · Multiple Myeloma
What this study did
NCT04939142 · Antengene Corporation
2021-07-12 – 2025-10-30 · Relapsed or Refractory Multiple Myeloma
What this study did
NCT01208766 · Stichting Hemato-Oncologie voor Volwassenen Nederland
2011-01 – 2025-01 · Multiple Myeloma
What this study did
NCT03234972 · Janssen Research & Development, LLC
2017-11-30 – 2024-02-27 · Multiple Myeloma
What this study did
NCT02136134 · Janssen Research & Development, LLC
2014-08-15 – 2024-01-10 · Multiple Myeloma
What this study did
NCT02541383 · Intergroupe Francophone du Myelome
2015-09 – 2023-09-01 · Multiple Myeloma
What this study did
NCT01241708 · Hackensack Meridian Health
2010-04-08 – 2023-07-15 · Multiple Myeloma, Auto Stem Cell Transplant
What this study did
NCT01554852 · University of Leeds
2010-05 – 2022-12 · Multiple Myeloma
What this study did
NCT01734928 · Celgene
2013-01-07 – 2022-05-13 · Multiple Myeloma
What this study did
NCT03110562 · Karyopharm Therapeutics Inc
2017-05-24 – 2022-05-12 · Multiple Myeloma
What this study did
NCT02495922 · University of Heidelberg Medical Center
2015-06 – 2021-06-24 · Multiple Myeloma
What this study did
NCT01146834 · Weill Medical College of Cornell University
2011-03 – 2019-02-04 · Multiple Myeloma
What this study did
NCT02197221 · University Hospital, Toulouse
2015-01 – 2018-12-31 · Multiple Myeloma
What this study did
NCT02811978 · Janssen Research & Development, LLC
2016-09-27 – 2018-11-10 · Multiple Myeloma
What this study did
NCT02362165 · Sun Yat-sen University
2015-04 – 2018-05 · Multiple Myeloma
What this study did
NCT01109004 · National Heart, Lung, and Blood Institute (NHLBI)
2010-05 – 2018-03-03 · Multiple Myeloma
What this study did
NCT01539083 · Janssen Scientific Affairs, LLC
2012-01-13 – 2018-01-09 · Multiple Myeloma
What this study did
Phase 2/3 (11)
Multiple Myeloma
NCT07887984 · Alliance for Clinical Trials in Oncology
2026-12-23 – 2053-08-01 · Multiple Myeloma (MM)
What this study did
NCT07428369 · Regeneron Pharmaceuticals
2026-06-05 – 2038-05-21 · Multiple Myeloma (MM)
What this study did
NCT05665140 · University Hopsital Schleswig Holstein Campus Lübeck
2023-02-03 – 2028-10 · Newly Diagnosed Multiple Myeloma
What this study did
NCT03759093 · National University Hospital, Singapore
2023-09-10 – 2025-09-10 · Multiple Myeloma
What this study did
NCT00984828 · Shanghai Jiao Tong University School of Medicine
2009-08 – 2016-12 · Multiple Myeloma
What this study did
NCT00861250 · Tampere University Hospital
2009-03 – 2015-07 · Multiple Myeloma
What this study did
NCT00514371 · Bristol-Myers Squibb
2007-08 – 2009-02 · Multiple Myeloma
What this study did
Other / comorbidity
NCT07072585 · Children's Oncology Group
2026-08-28 – 2035-09-01 · Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma, Stage IV T Lymphoblastic Leukemia/Lymphoma, T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma
What this study did
NCT03117751 · St. Jude Children's Research Hospital
2017-03-29 – 2028-09-30 · Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma
What this study did
NCT03474458 · Fondazione IRCCS Policlinico San Matteo di Pavia
2019-02-11 – 2022-05-30 · Cardiac AL Amyloidosis
What this study did
NCT01805557 · Fondazione Italiana Linfomi - ETS
2013-02-04 – 2020-11-20 · Diffuse Large B-cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent
What this study did
Phase 2 (432)
Mantle Cell Lymphoma
NCT01415752 · Eastern Cooperative Oncology Group
2012-08-09 – 2031-09 · Lymphoma, Mantle Cell Lymphoma
What this study did
NCT03617484 · University of Michigan Rogel Cancer Center
2020-07 – 2030-07 · Mantle Cell Lymphoma
What this study did
NCT04626791 · Academic and Community Cancer Research United
2021-08-03 – 2028-08-03 · Mantle Cell Lymphoma
What this study did
NCT06656221 · Ruijin Hospital
2024-12-01 – 2028-05-01 · Mantle Cell Lymphoma
What this study did
NCT05564052 · Janssen Research & Development, LLC
2022-12-06 – 2024-09-26 · Lymphoma, Mantle-Cell
What this study did
NCT02840539 · Seoul National University Hospital
2016-10-11 – 2022-12-31 · Mantle Cell Lymphoma
What this study did
NCT00114738 · National Cancer Institute (NCI)
2005-06-15 – 2022-08-11 · Lymphoma, Mantle Cell, Mantle Cell Lymphoma
What this study did
NCT00310037 · Alliance for Clinical Trials in Oncology
2006-06 – 2022-06 · Mantle Cell Lymphoma
What this study did
NCT03016988 · Tingbo Liu
2017-01 – 2020-12 · Mantle Cell Lymphoma
What this study did
NCT01267812 · City of Hope Medical Center
2011-10-03 – 2020-11-02 · Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Stage I Mantle Cell Lymphoma, Stage III Mantle Cell Lymphoma, Stage IV Mantle Cell Lymphoma
What this study did
NCT00992446 · Fred Hutchinson Cancer Center
2010-09-02 – 2019-10-29 · Adult Diffuse Large B-Cell Lymphoma, B-Cell Non-Hodgkin Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Non-Hodgkin Lymphoma, T-Cell Non-Hodgkin Lymphoma
What this study did
NCT00980395 · University of Arizona
2009-07-07 – 2018-08-14 · Lymphoma, Mantle Cell Lymphoma, Indolent Lymphoma, SLL
What this study did
NCT00711828 · Mayo Clinic
2008-08 – 2018-04-06 · Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Splenic Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
What this study did
NCT00703664 · National Cancer Institute (NCI)
2008-07-09 – 2017-12-01 · Recurrent Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma
What this study did
NCT00376961 · SWOG Cancer Research Network
2006-08 – 2017-09 · Lymphoma
What this study did
NCT02877082 · Emory University
2016-09 – 2017-07 · Acute Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Graft Versus Host Disease, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Small Lymphocytic Lymphoma
What this study did
NCT00740415 · French Innovative Leukemia Organisation
2007-06 – 2015-08 · Lymphoma
What this study did
NCT00581776 · University of Wisconsin, Madison
2005-05 – 2015-05 · Mantle Cell Lymphoma
What this study did
NCT00513955 · University Hospital Plymouth NHS Trust
2006-06 – 2014-10 · Lymphoma
What this study did
NCT01497275 · Duke University
2012-02 – 2014-05 · Mantle-Cell Lymphoma
What this study did
NCT00958256 · M.D. Anderson Cancer Center
2009-08 – 2014-03 · Mantle Cell Lymphoma, Lymphoma
What this study did
NCT00553644 · National Cancer Institute (NCI)
2007-11-15 – 2014-01-21 · Recurrent Mantle Cell Lymphoma
What this study did
NCT01397591 · OHSU Knight Cancer Institute
2011-10 – 2013-07 · Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma
What this study did
NCT00433537 · National Cancer Institute (NCI)
2007-05 – 2013-06 · Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Stage I Mantle Cell Lymphoma, Stage III Mantle Cell Lymphoma, Stage IV Mantle Cell Lymphoma
What this study did
NCT00201877 · Ohio State University Comprehensive Cancer Center
2004-12 – 2012-03 · Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma
What this study did
NCT00377052 · NCIC Clinical Trials Group
2007-01-16 – 2011-06-21 · Lymphoma
What this study did
NCT00030875 · NCIC Clinical Trials Group
2002-11-19 – 2009-12-21 · Lymphoma
What this study did
NCT00023764 · National Cancer Institute (NCI)
2001-06 – 2009-03 · Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma
What this study did
NCT00261612 · Medical University of Vienna
2005-01 – 2007-01 · Lymphoma, Mantle-Cell
What this study did
Multiple Myeloma
NCT07247097 · Massachusetts General Hospital
2026-08-01 – 2035-12-01 · Multiple Myeloma, Newly Diagnosed Multiple Myeloma, Transplant Ineligible, Newly Diagnosed Multiple Myeloma (NDMM)
What this study did
NCT05272826 · Canadian Myeloma Research Group
2024-12-12 – 2031-03 · Multiple Myeloma
What this study did
NCT07614360 · GlaxoSmithKline
2026-08-03 – 2031-02-11 · Multiple Myeloma
What this study did
DARA RVD For High Risk SMMactive not recruiting
NCT04775550 · Omar Nadeem, MD
2021-03-08 – 2030-12-08 · High-risk Smoldering Multiple Myeloma, Multiple Myeloma
What this study did
NCT04240054 · Medical College of Wisconsin
2021-11-02 – 2030-12-01 · Multiple Myeloma
What this study did
NCT06353022 · Nantes University Hospital
2024-06-26 – 2030-06-26 · Multiple Myeloma
What this study did
NCT07045909 · PETHEMA Foundation
2025-06-30 – 2030-03-31 · De Novo Multiple Myeloma, Anitocabtagene Autoleucel
What this study did
NCT05695508 · University of Heidelberg Medical Center
2022-12-01 – 2029-09-15 · Multiple Myeloma
What this study did
NCT05849610 · PETHEMA Foundation
2023-09-21 – 2029-07 · High-Risk de Novo Multiple Myeloma
What this study did
NCT04717700 · Ida Bruun Kristensen
2021-08-18 – 2029-06-01 · Multiple Myeloma
What this study did
NCT07891923 · Tata Memorial Centre
2025-10-28 – 2029-05-05 · Newly Diagnosed Multiple Myeloma (NDMM)
What this study did
NCT06348147 · UNC Lineberger Comprehensive Cancer Center
2026-07 – 2029-05 · Newly Diagnosed Multiple Myeloma, Multiple Myeloma, Autologous Stem Cell Transplantation
What this study did
NCT04653246 · Jacob Laubach, MD
2021-07-13 – 2029-01-13 · Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Autologous Stem Cell Transplant
What this study did
NCT07789522 · Institute of Hematology & Blood Diseases Hospital, China
2026-10-01 – 2028-10-30 · Multiple Myeloma (MM)
What this study did
NCT00869232 · University of Arkansas
2008-10 – 2028-10 · Multiple Myeloma
What this study did
NCT03004287 · University of Arkansas
2017-07-01 – 2028-10 · Multiple Myeloma
What this study did
Phase 1/2 (114)
Mantle Cell Lymphoma
NCT01381692 · National Cancer Institute (NCI)
2011-07-20 – 2021-09-01 · Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma
What this study did
NCT02356458 · Swiss Cancer Institute
2015-08-31 – 2021-03-30 · Mantle Cell Lymphoma
What this study did
NCT00477412 · M.D. Anderson Cancer Center
2007-04-03 – 2020-10-28 · Mantle Cell Lymphoma
What this study did
NCT00633594 · SCRI Development Innovations, LLC
2008-06 – 2016-11 · Mantle Cell Lymphoma
What this study did
NCT00571493 · University of Nebraska
2006-04-14 – 2014-11-01 · Non-hodgkin's Lymphoma, Mantle Cell Lymphoma
What this study did
NCT01460602 · Louisiana State University Health Sciences Center Shreveport
2010-05 – 2014-10 · Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma
What this study did
NCT01322776 · Sun Yat-sen University
2011-03 – 2013-10 · Mantle Cell Lymphoma Recurrent
What this study did
Multiple Myeloma
NCT07600151 · Universitätsklinikum Hamburg-Eppendorf
2026-12-01 – 2036-12-31 · Myeloma Multiple, Myeloma
What this study did
NCT07601100 · Dana-Farber Cancer Institute
2026-09-03 – 2034-07-01 · Newly Diagnosed Multiple Myeloma
What this study did
NCT05392946 · Mayo Clinic
2022-08-11 – 2028-09-29 · Plasma Cell Myeloma
What this study did
NCT02773030 · Celgene
2016-10-14 – 2028-07-28 · Multiple Myeloma
What this study did
NCT05514990 · University of Southern California
2022-10-07 – 2027-08-22 · Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
What this study did
NCT02343042 · Karyopharm Therapeutics Inc
2015-10 – 2027-04 · Multiple Myeloma
What this study did
NCT04068597 · CellCentric Ltd.
2019-08-09 – 2027-03-31 · Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma, Higher-risk Myelodysplastic Syndrome, Peripheral T Cell Lymphoma
What this study did
NCT00378105 · Dana-Farber Cancer Institute
2006-09 – 2026-12 · Multiple Myeloma
What this study did
NCT05422027 · Xia Zhongjun
2022-07-25 – 2025-12-31 · Multiple Myeloma
What this study did
NCT01668719 · SWOG Cancer Research Network
2012-11 – 2025-09-22 · DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma
What this study did
NCT00995059 · Mayo Clinic
— · Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT04445701 · Arch Oncology
2020-11-30 – 2022-11-14 · Multiple Myeloma
What this study did
NCT03481556 · Oncopeptides AB
2018-04-12 – 2022-02-02 · Multiple Myeloma
What this study did
NCT02605356 · Bayer
2016-10 – 2021-07 · Multiple Myeloma
What this study did
NCT03136653 · Molecular Partners AG
2017-05-23 – 2021-01-13 · Multiple Myeloma in Relapse
What this study did
NCT03701321 · National Cancer Institute (NCI)
2019-01-25 – 2020-05-28 · Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
What this study did
NCT01212952 · Mayo Clinic
2011-09 – 2018-03-22 · Refractory Multiple Myeloma
What this study did
NCT01672736 · University Health Network, Toronto
2012-09 – 2017-12-27 · Multiple Myeloma
What this study did
NCT01177683 · Sherif Farag, MB, BS
2010-07 – 2017-12 · Multiple Myeloma
What this study did
NCT01827137 · Sellas Life Sciences Group
2013-04 – 2017-11-06 · Multiple Myeloma
What this study did
NCT01522872 · Threshold Pharmaceuticals
2012-02 – 2017-09 · Multiple Myeloma
What this study did
NCT01460420 · European Myeloma Network B.V.
2011-11 – 2017-06-29 · Hematologic Malignancies, Multiple Myeloma
What this study did
NCT01812096 · The First Affiliated Hospital of Soochow University
2014-05 – 2017-06 · Multiple Myeloma Proved by Laboratory Tests
What this study did
NCT00903968 · Dana-Farber Cancer Institute
2009-06-01 – 2016-10 · Multiple Myeloma
What this study did
NCT01242267 · Hackensack Meridian Health
2010-05-11 – 2016-01-20 · Multiple Myeloma
What this study did
NCT02145715 · Prof Jamie Cavenagh
2013-01 – 2016-01 · Multiple Myeloma
What this study did
NCT01394354 · University Hospital Freiburg
2011-08 – 2015-12 · Multiple Myeloma in Relapse
What this study did
NCT00849251 · University of Washington
2008-11 – 2015-06 · Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
What this study did
NCT01183949 · Astex Pharmaceuticals, Inc.
2010-11 – 2015-03 · Multiple Myeloma
What this study did
NCT01255527 · Yonsei University
2010-10 – 2014-12 · Multiple Myeloma Patients Who Candidate for Autologous Peripheral Blood Stem Cell Transplantation
What this study did
NCT01034553 · Mayo Clinic
2010-02 – 2014-11 · Refractory Multiple Myeloma
What this study did
NCT00724568 · University of Michigan Rogel Cancer Center
2008-05 – 2014-09-03 · Multiple Myeloma
What this study did
NCT01531998 · M.D. Anderson Cancer Center
2012-05 – 2014-05 · Myeloma
What this study did
NCT00784823 · Hackensack Meridian Health
2007-01 – 2013-12 · Multiple Myeloma
What this study did
NCT01063907 · Kyowa Kirin Co., Ltd.
2010-03 – 2013-11 · Multiple Myeloma
What this study did
NCT00750815 · H. Lee Moffitt Cancer Center and Research Institute
2008-09 – 2013-05 · Multiple Myeloma
What this study did
NCT00084747 · Jonsson Comprehensive Cancer Center
2004-06 – 2013-01 · Multiple Myeloma and Plasma Cell Neoplasm
What this study did
NCT00719901 · National Cancer Institute (NCI)
2008-07 – 2012-06 · Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
What this study did
NCT00483262 · Dana-Farber Cancer Institute
2007-05 – 2012-02 · Multiple Myeloma
What this study did
NCT00431990 · Peter MacCallum Cancer Centre, Australia
2006-11 – 2012-01 · Multiple Myeloma
What this study did
Phase 1 (186)
Mantle Cell Lymphoma
NCT01695941 · National Cancer Institute (NCI)
2012-08-31 – 2027-03-03 · Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma
What this study did
NCT01439750 · Milton S. Hershey Medical Center
2012-05 – 2020-08 · Mantle Cell Lymphoma
What this study did
NCT01111188 · Weill Medical College of Cornell University
2010-08-23 – 2019-04-12 · Mantle Cell Lymphoma
What this study did
NCT00082784 · National Cancer Institute (NCI)
2004-03 – 2014-09 · Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory Plasma Cell Myeloma, Splenic Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
What this study did
NCT01504776 · Anand Jillella
2011-04 – 2014-09 · Mantle Cell Lymphoma
What this study did
NCT00791011 · Amgen
2008-02 – 2011-08 · Hodgkin's Lymphoma, Low Grade Lymphoma, Lymphoma, Mantle Cell Lymphoma, Non-Hodgkin's Lymphoma, Diffuse Large Cell Lymphoma
What this study did
NCT00538187 · National Cancer Institute (NCI)
2007-12 – 2011-04 · Adult Non-Hodgkin Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma
What this study did
NCT00096005 · National Cancer Institute (NCI)
2004-11 – 2010-03 · Adult Grade III Lymphomatoid Granulomatosis, AIDS-related Peripheral/Systemic Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Stage IV Small Lymphocytic Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Waldenström Macroglobulinemia
What this study did
NCT00348985 · National Cancer Institute (NCI)
2006-03 – 2010-01 · Adult Grade III Lymphomatoid Granulomatosis, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Primary Central Nervous System Hodgkin Lymphoma, Primary Central Nervous System Non-Hodgkin Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Splenic Marginal Zone Lymphoma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Stage IV Small Lymphocytic Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Waldenström Macroglobulinemia
What this study did
NCT00054483 · National Cancer Institute (NCI)
2003-01 – 2009-09 · Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Multiple Myeloma, Splenic Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Waldenström Macroglobulinemia
What this study did
NCT00068315 · National Cancer Institute (NCI)
2003-07 – 2008-12 · Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hematopoietic/Lymphoid Cancer, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Splenic Marginal Zone Lymphoma, Waldenström Macroglobulinemia
What this study did
NCT00103272 · National Cancer Institute (NCI)
2005-04 – 2008-04 · Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Waldenström Macroglobulinemia
What this study did
Multiple Myeloma
NCT07609706 · GlaxoSmithKline
2026-10-23 – 2031-08-22 · Multiple Myeloma
What this study did
NCT07341867 · Andrew Hantel, MD
2026-07-30 – 2029-03-31 · Multiple Myeloma, Triple Negative Breast Cancer, Duffy Blood Group, Chemokine Receptor Gene Mutation, Duffy Blood Group, Chemokine Receptor Gene C.-67T>C
What this study did
NCT04091126 · GlaxoSmithKline
2019-12-18 – 2028-03-10 · Multiple Myeloma
What this study did
NCT04722146 · Janssen Research & Development, LLC
2021-03-12 – 2027-10-13 · Multiple Myeloma
What this study did
NCT03984097 · Takeda
2019-07-29 – 2026-03-25 · Multiple Myeloma
What this study did
NCT03828292 · GlaxoSmithKline
2019-03-14 – 2024-09-05 · Multiple Myeloma
What this study did
NCT05052970 · CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
2021-10-20 – 2024-06-20 · Relapsed or Refractory Multiple Myeloma
What this study did
NCT05556616 · Teva Branded Pharmaceutical Products R&D LLC
2023-01-12 – 2024-06-04 · Multiple Myeloma
What this study did
NCT01163357 · City of Hope Medical Center
2011-03-01 – 2024-05-20 · Autologous Hematopoietic Stem Cell Transplant Recipient, Loss of Chromosome 17p, Plasma Cell Leukemia, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
What this study did
NCT04912427 · Washington University School of Medicine
2022-04-01 – 2024-01-26 · Multiple Myeloma
What this study did
NCT01998971 · Janssen Research & Development, LLC
2014-02-18 – 2024-01-11 · Multiple Myeloma
What this study did
NCT03829020 · Mayo Clinic
2019-04-17 – 2023-11-24 · Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
What this study did
NCT04392648 · Teva Branded Pharmaceutical Products R&D LLC
2020-06-24 – 2023-11-10 · Relapsed and/or Refractory Multiple Myeloma
What this study did
NCT03051841 · Chong Kun Dang Pharmaceutical
2017-01 – 2022-11 · Myeloma, Multiple
What this study did
NCT04956302 · Abdullah Khan
2021-09-27 – 2022-06-16 · Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
What this study did
NCT02514382 · University of Southern California
2015-08-21 – 2022-04-19 · Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
What this study did
NCT02658396 · Dana-Farber Cancer Institute
est. completion 2022-01 · Multiple Myeloma, Multiple Myeloma in Relapse, Refractory Multiple Myeloma
What this study did
NCT01965353 · Dana-Farber Cancer Institute
2013-10 – 2021-09 · Multiple Myeloma in Relapse
What this study did
NCT01038388 · Emory University
2010-01-15 – 2021-08-05 · Multiple Myeloma
What this study did
NCT00720785 · National Heart, Lung, and Blood Institute (NHLBI)
2008-08-01 – 2021-04-06 · Chronic Myeloid Leukemia (CML), Pancreatic Ca, Colon/Rectal Ca, Multiple Myeloma, Carcinoma, Non-Small -Cell Lung
What this study did
NCT03878524 · OHSU Knight Cancer Institute
2020-04-01 – 2020-12-10 · Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Castration-Resistant Prostate Carcinoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Primary Myelofibrosis, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Chronic Myelomonocytic Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Myelodysplastic Syndrome, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Plasma Cell Myeloma, Refractory Primary Myelofibrosis, Refractory Small Lymphocytic Lymphoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
What this study did
NCT02955810 · National University of Ireland, Galway, Ireland
2016-11 – 2020-11 · Multiple Myeloma
What this study did
NCT01794507 · AbbVie
2012-11-19 – 2019-07-16 · Relapsed/Refractory Multiple Myeloma
What this study did
NCT01440582 · M.D. Anderson Cancer Center
2013-02-18 – 2019-02-28 · Myeloma
What this study did
NCT02100657 · PharmaMar
2014-06 – 2018-06 · Multiple Myeloma
What this study did
NCT02497378 · Janssen Pharmaceutical K.K.
2015-07-10 – 2018-03-06 · Multiple Myeloma
What this study did
NCT01936090 · Mayo Clinic
2013-08 – 2018-02-16 · DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
What this study did
NCT01954784 · Case Comprehensive Cancer Center
2013-10-07 – 2017-01-30 · Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
What this study did
NCT02220608 · Washington University School of Medicine
2015-02-20 – 2016-11-30 · Multiple Myeloma
What this study did
NCT01711528 · National Cancer Institute (NCI)
2012-12-19 – 2016-11-22 · Recurrent Plasma Cell Myeloma
What this study did
NCT02481934 · Joaquín Martínez López, MD, PhD
2013-03 – 2016-10 · Multiple Myeloma
What this study did
NCT01248923 · Array Biopharma, now a wholly owned subsidiary of Pfizer
2010-12 – 2016-03 · Multiple Myeloma, Plasma Cell Leukemia
What this study did
NCT01359657 · Bristol-Myers Squibb
2011-09 – 2016-03 · Multiple Myeloma
What this study did
Phase 4 (23)
Multiple Myeloma
NCT03829371 · University of Turin, Italy
2019-01-03 – 2030-01-03 · Multiple Myeloma
What this study did
Isa-VRD in TIE HRMMnot yet recruiting
NCT07334535 · Peking Union Medical College Hospital
2026-01-30 – 2029-01 · Multiple Myeloma
What this study did
NCT07025005 · Tanta University
2025-08-30 – 2026-09-30 · Peripheral Neuropathy, Multiple Myeloma, Neoplasms
What this study did
NCT04348006 · Al-Rasheed University College
2020-03-01 – 2021-07-30 · Newly Diagnosed Multiple Myeloma
What this study did
NCT02559154 · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
2010-07 – 2018-12 · Multiple Myeloma
What this study did
NCT02773550 · Basque Health Service
2014-01 – 2018-07 · Multiple Myeloma
What this study did
NCT01868828 · Peking University People's Hospital
2013-05 – 2017-05 · Multiple Myeloma
What this study did
NCT02268890 · Johnson & Johnson Taiwan Ltd
2014-12 – 2015-07 · Multiple Myeloma
What this study did
NCT01249690 · Second Military Medical University
2010-06 – 2014-06 · Multiple Myeloma
What this study did
NCT00257114 · Millennium Pharmaceuticals, Inc.
est. completion 2007-03 · Multiple Myeloma
What this study did
Other / comorbidity
NCT06015750 · Alexion Pharmaceuticals, Inc.
2026-07-29 – 2030-03-13 · Hypophosphatasia
What this study did
NCT03844360 · Wei Zhao
2016-01-31 – 2026-12-31 · Hematological Neoplasms
What this study did
NCT05135442 · Peking Union Medical College Hospital
2021-12-01 – 2025-11-30 · Thrombotic Thrombocytopenic Purpura, Acquired
What this study did
NCT05137860 · Hospital General de Mexico
2021-12-12 – 2023-06-23 · Acute Lymphoblastic Leukemia, in Relapse, Chemotherapeutic Toxicity, Minimal Residual Disease
What this study did
NCT02844322 · Institute of Hematology & Blood Diseases Hospital, China
2016-05 – 2023-05 · Waldenström Macroglobulinemia
What this study did
NCT02525172 · National Taiwan University Hospital
2015-08 – 2020-07 · Pompe Disease
What this study did
NCT01842074 · Assistance Publique - Hôpitaux de Paris
2013-03 – 2018-03 · Patients Awaiting a Living Kidney Donation
What this study did
NCT01103778 · The Rogosin Institute
2010-07 – 2017-04-17 · Chronic Kidney Disease, IgA Nephropathy
What this study did
NCT00782821 · University of Cincinnati
2008-09 – 2013-03 · Kidney Transplantation
What this study did
NCT01169857 · The Rogosin Institute
2010-08 – 2012-12 · Lupus Nephritis, Proteinuria, Hematuria
What this study did
NCT00908583 · University of Cincinnati
2009-05 – 2012-11 · HLA Sensitization
What this study did
Early phase / not applicable (21)
Mantle Cell Lymphoma
NCT02037256 · Barbara Ann Karmanos Cancer Institute
2011-07 – 2015-01-21 · Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Burkitt Lymphoma, Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Contiguous Stage II Adult Lymphoblastic Lymphoma, Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Grade 3 Follicular Lymphoma, Contiguous Stage II Mantle Cell Lymphoma, Contiguous Stage II Marginal Zone Lymphoma, Contiguous Stage II Small Lymphocytic Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Progressive Hairy Cell Leukemia, Initial Treatment, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage I Adult Burkitt Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Mixed Cell Lymphoma, Stage I Adult Diffuse Small Cleaved Cell Lymphoma, Stage I Adult Immunoblastic Large Cell Lymphoma, Stage I Adult Lymphoblastic Lymphoma, Stage I Grade 1 Follicular Lymphoma, Stage I Grade 2 Follicular Lymphoma, Stage I Grade 3 Follicular Lymphoma, Stage I Mantle Cell Lymphoma, Stage I Marginal Zone Lymphoma, Stage I Multiple Myeloma, Stage I Small Lymphocytic Lymphoma, Stage II Multiple Myeloma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma, Untreated Hairy Cell Leukemia, Waldenström Macroglobulinemia
What this study did
Multiple Myeloma
NCT05889221 · Poitiers University Hospital
2023-10-23 – 2028-09-01 · Multiple Myeloma, Myeloma Multiple, Myeloma
What this study did
NCT06203145 · Peking University First Hospital
2024-01-02 – 2025-11-30 · Multiple Myeloma, Renal Injury
What this study did
NCT07614243 · The First Affiliated Hospital of Zhejiang Chinese Medical University
2020-08-01 – 2022-08-31 · Multiple Myeloma, Chemotherapy-Induced Peripheral Neuropathy
What this study did
NCT01383759 · Memorial Sloan Kettering Cancer Center
2011-06-24 – 2019-04-30 · Light Chain Deposition Disease (LCDD or MIDD), Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD), Monoclonal Immunoglobulin Deposition Disease (MIDD), Amyloidosis
What this study did
NCT07774988 · Can Lafci
2018-02-05 – 2018-08-31 · Multiple Myeloma
What this study did
NCT01541644 · University of Maryland, Baltimore
2011-05 – 2014-12 · Peripheral Neuropathies, Multiple Myeloma
What this study did
NCT00569868 · University of Arkansas
2005-08 – 2008-01 · MULTIPLE MYELOMA
What this study did
NCT00135187 · University of Michigan Rogel Cancer Center
2004-07 – 2007-12 · Multiple Myeloma
What this study did
Other / comorbidity
NCT06192979 · Jin Lu, MD
2024-01-05 – 2027-03-31 · Amyloidosis; Systemic, AL Amyloidosis
What this study did
NCT06876298 · Assiut University
2025-03-25 – 2027-03-25 · Multiple Myloma
What this study did
NCT05805891 · Chinese SLE Treatment And Research Group
2023-12 – 2025-12 · Rheumatoid Arthritis
What this study did
NCT03390387 · Federal Research Institute of Pediatric Hematology, Oncology and Immunology
2015-11 – 2025-11 · Childhood Acute Lymphoblastic Leukemia
What this study did
NCT03737136 · Shahid Beheshti University of Medical Sciences
2019-11-01 – 2025-09-01 · Antibody-mediated Rejection
What this study did
NCT06215638 · Peking Union Medical College Hospital
2023-03-01 – 2024-12-30 · Rheumatoid Arthritis
What this study did
NCT05383547 · Ruijin Hospital
2022-08-02 – 2023-12-31 · Bortezomib, Glomerulonephritis, MN, MPGN, FSGS, IgA Nephropathy
What this study did
NCT03401372 · Jian Li
2018-04-21 – 2020-12-31 · Amyloidosis; Systemic
What this study did
NCT01273844 · Zhi-Hong Liu, M.D.
2011-03-01 – 2016-05-12 · Amyloidosis
What this study did
NCT01350232 · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
2009-09 – 2011-08 · Sickle Cell Anemia, Sickle Cell-hemoglobin C Disease, Sickle Cell-β0-thalassemia
What this study did
NCT00772668 · University of Miami
2009-09-25 – 2011-02 · Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma
What this study did
NCT00789256 · Dartmouth-Hitchcock Medical Center
2004-09 – 2008-12 · Acute Myelogenous Leukemia, Myelodysplastic Syndromes
What this study did
Used as active comparator (32)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (27)
Multiple Myeloma
NCT07671287 · University of Heidelberg Medical Center
2026-06-30 – 2033-01-30 · Multiple Myeloma
What this study did
NCT06413498 · Kite, A Gilead Company
2024-08-23 – 2031-07 · Multiple Myeloma
What this study did
NCT05561387 · SWOG Cancer Research Network
2023-10-12 – 2031-05-30 · Plasma Cell Myeloma
What this study did
NCT03742297 · PETHEMA Foundation
2018-10-22 – 2031-01 · Newly Diagnosed Multiple Myeloma
What this study did
NCT06464991 · Nanjing IASO Biotechnology Co., Ltd.
2024-03-27 – 2030-12 · Multiple Myeloma
What this study did
NCT07933432 · Qilu Pharmaceutical Co., Ltd.
2026-12-30 – 2030-05-21 · Relapsed or Refractory Multiple Myeloma
What this study did
NCT07623798 · Innovent Biologics (Suzhou) Co. Ltd.
2026-06-11 – 2029-12-31 · Relapsed or Refractory Multiple Myeloma
What this study did
NCT04484623 · GlaxoSmithKline
2020-10-01 – 2029-06-25 · Multiple Myeloma
What this study did
NCT06956170 · GlaxoSmithKline
2022-02-10 – 2029-06-25 · Multiple Myeloma
What this study did
NCT07579234 · Shandong New Time Pharmaceutical Co., LTD
2026-01-25 – 2029-01-25 · Relapsed or Refractory Multiple Myeloma (RRMM)
What this study did
NCT05675319 · Universitätsklinikum Hamburg-Eppendorf
2023-03-03 – 2025-03-21 · Multiple Myeloma
What this study did
NCT01568866 · Amgen
2012-06-20 – 2018-02-05 · Multiple Myeloma
What this study did
NCT01818752 · Amgen
2013-07-08 – 2016-11-04 · Multiple Myeloma
What this study did
NCT00602511 · Nordic Myeloma Study Group
2007-10 – 2010-12 · Multiple Myeloma
What this study did
Other / comorbidity
NCT07901725 · Regeneron Pharmaceuticals
2026-12-18 – 2035-07-25 · Newly Diagnosed Amyloidosis, Amyloidosis Stage I-IIIA
What this study did
NCT01998503 · Nanjing University School of Medicine
2007-12 – 2013-08 · Amyloidosis
What this study did
Phase 2 (3)
Mantle Cell Lymphoma
NCT00871546 · Merck Sharp & Dohme LLC
2009-03 – 2010-12 · Lymphoma, Mantle-Cell, Leukemia, Lymphocytic, Chronic, B-Cell
What this study did
Multiple Myeloma
NCT00095680 · Scios, Inc.
2004-11 – 2006-02 · Multiple Myeloma
What this study did
Phase 1/2 (1)
Multiple Myeloma
NCT03607643 · Leaf Vertical Inc.
2019-01-15 – 2020-12-15 · Cancer of Pancreas, Cancer of Liver, Cancer of Rectum, Cancer of Colon, Cancer, Gall Bladder, Myeloma Multiple, Glioblastoma Multiforme
What this study did
Phase 1 (1)
Multiple Myeloma
NCT00884546 · Bristol-Myers Squibb
2009-07 – 2012-03 · Advanced Cancer, Various, NOS
What this study did
Appears in other studies (19)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (9)
Multiple Myeloma
NCT01208662 · Paul Richardson, MD
2010-09 – 2026-12 · Multiple Myeloma
What this study did
NCT02755597 · AbbVie
2016-07-11 – 2022-08-15 · Relapsed/Refractory Multiple Myeloma
What this study did
NCT01470131 · AB Science
2011-05 – 2017-02-01 · Multiple Myeloma
What this study did
NCT01023308 · Novartis Pharmaceuticals
2009-12-21 – 2015-07-30 · Multiple Myeloma
What this study did
NCT00773747 · Merck Sharp & Dohme LLC
2008-12-01 – 2015-06-30 · Multiple Myeloma
What this study did
NCT01002248 · AEterna Zentaris
2009-12 – 2013-03 · Multiple Myeloma
What this study did
Other / comorbidity
NCT05681260 · Children's Cancer Group, China
2023-02-06 – 2029-12-31 · T-cell Lymphoblastic Lymphoma
What this study did
NCT04504825 · Alexion Pharmaceuticals, Inc.
2020-08-25 – 2027-10-22 · AL Amyloidosis
What this study did
NCT04512235 · Alexion Pharmaceuticals, Inc.
2020-11-03 – 2027-04-08 · AL Amyloidosis
What this study did
Phase 2 (7)
Multiple Myeloma
NCT02440464 · National Heart, Lung, and Blood Institute (NHLBI)
2015-08 – 2020-10-01 · Multiple Myeloma
What this study did
NCT01602224 · Eli Lilly and Company
2012-07 – 2014-07 · Multiple Myeloma
What this study did
NCT01337752 · Novartis Pharmaceuticals
2012-01 – 2013-05 · Multiple Myeloma, Renal Insufficiency
What this study did
NCT00315757 · Human Genome Sciences Inc.
2006-05 – 2010-10 · Multiple Myeloma
What this study did
NCT00473590 · Genentech, Inc.
2007-06 – 2009-11 · Multiple Myeloma
What this study did
Other / comorbidity
NCT01332617 · University of Louisville
2011-04 – 2019-02 · Myeloma
What this study did
NCT00064012 · University of Wisconsin, Madison
2003-05 – 2004-07 · Lung Cancer
What this study did
Phase 1/2 (2)
Multiple Myeloma
NCT02928029 · Bayer
2017-02-10 – 2019-03-20 · Multiple Myeloma
What this study did
Other / comorbidity
NCT02563340 · First Affiliated Hospital, Sun Yat-Sen University
2015-11 – 2017-11 · Kidney Transplantation
What this study did
Phase 1 (1)
Multiple Myeloma
NCT06142396 · Augusta University
2024-11-01 – 2027-11-01 · Multiple Myeloma, Renal Failure
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Multiple Myeloma: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Bortezomib: this drugApprovedSmall moleculeProteasomePartial signal
NCT00722566: Number of Patients With Overall Response (Complete Response + Partial Response) (Over 4 cycles (prior to the addition of dexamethasone)): VELCADE Subcutaneuous 61/145 | VELCADE Intravenous 31/73
NCT00048230: Response rate (CR+PR): 38% bortezomib vs 18% dexamethasone (P<0.001), with CR 6% vs <1%; median time to progression 6.22 vs 3.49 months (HR 0.55, P<0.001); 1-year survival 80% vs 66% (P=0.003), overall survival HR 0.57 (P=0.001).
Belantamab MafodotinApprovedAntibody–drug conjugateBCMAPartial signal
NCT04246047: Progression-free Survival (PFS) (Up to approximately 41 months): Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex) 36.6 Months vs Daratumumab + Bor + Dex 13.4 Months (95% CI 11.1 to 17.5)
NCT04162210: Progression-Free Survival (PFS) Based on Investigator-Assessed Response as Per International Myeloma Working Group (IMWG) (Up to 27 months): Belantamab Mafodotin 11.2 Months (95% CI 6.4 to 14.5) vs Pomalidomide Plus Dexamethasone 7 Months (95% CI 4.6 to 10.6) missed
CarfilzomibApprovedSmall moleculeProteasomePartial signal
NCT03158688: Progression-free Survival (PFS) as Assessed by the Independent Review Committee (PA DCO Only) (From randomization until the PA DCO date of 14 July 2019; the longest treatment duration as of the DCO was 102.3 weeks): Kd - Carfilzomib and Dexamethasone — Participants with PFS events: 68 Participants; Participants who were censored: 86 Participants | KdD - Carfilzomib, Dexamethasone and Daratumumab — Participants with PFS events: 110 Participants; Participants who were censored: 202 Participants
NCT01568866: Progression-free Survival (From randomization until the data cut-off date of 10 November 2014; median follow-up time for PFS was 11.1.and 11.9 months in the bortezomib and carfilzomib arms respectively): Carfilzomib + DEX 18.7 months vs Bortezomib + DEX 9.4 months (95% CI 8.4 to 10.4)
Ciltacabtagene AutoleucelApprovedCell therapyBCMAPartial signal
NCT04181827: Progression-free survival: median not reached with cilta-cel vs 11.8 months with standard care (hazard ratio 0.26; 95% CI 0.18 to 0.38; P<0.001); 12-month PFS 75.9% vs 48.6% (CARTITUDE-4, N Engl J Med 2023).
DaratumumabApprovedMonoclonal antibodyCD38Partial signal
NCT03901963: Percentage of Participants Who Had Minimal Residual Disease (MRD) Conversion From Baseline to 12 Months After Start of Maintenance Treatment as Determined by Next Generation Sequencing (NGS) (From randomization up to 12 months): Daratumumab + Lenalidomide 50.5% (95% CI 40.3 to 60.7) vs Lenalidomide 18.8% (95% CI 11.7 to 27.8)
NCT02076009: Progression-free survival at the interim analysis: hazard ratio 0.37 (95% CI 0.27 to 0.52; P<0.001); 12-month PFS 83.2% with daratumumab plus lenalidomide/dexamethasone vs 60.1% with lenalidomide/dexamethasone (POLLUX, N Engl J Med 2016).
ElotuzumabApprovedMonoclonal antibodySLAMF7 (CS1/CD319)Partial signal
NCT01335399: Progression-Free Survival (PFS) (From randomization to date of first documented tumor progression or death due to any cause (up to 8 years)): E-Ld Cohort 31.38 Months (95% CI 26.18 to 36.8) vs Ld Cohort 29.47 Months (95% CI 23.49 to 34.3) missed
NCT01239797: Median Progression Free Survival (PFS) (From randomization up to 326 events (up to approximately 38 months)): Lenalidomide + Dexamethasone + Elotuzumab 19.35 Months (95% CI 16.62 to 22.18) vs Lenalidomide + Dexamethasone 14.85 Months (95% CI 12.09 to 17.22)
ElranatamabApprovedMultispecific antibodyBCMA x CD3Weak signalFeatured results are non-efficacy only in this race
Iberdomide (Zenbexus)ApprovedSmall moleculeCereblon E3 ubiquitin-ligasenot yet gradedNo reviewed efficacy summary in this indication
Idecabtagene VicleucelApprovedCell therapyBCMAReliable signal
NCT03651128: PFS 13.3 vs 4.4 mo (HR 0.49 [95% CI 0.38-0.65], p<0.001); ORR 71% vs 42% (p<0.001)
NCT03361748: Overall Response Rate (From first dose to 24 Months): BB2121 74.5% (95% CI 67.1 to 81.8)
IsatuximabApprovedMonoclonal antibodyCD38Partial signal
NCT02990338: Progression Free Survival (PFS) (From the date of randomization to the date of first documentation of progression, or the date of death from any cause, or initiation of further anti-myeloma treatment or data cut-off whichever comes first (maximum duration: 76.7 weeks)): IPd (Isatuximab + Pomalidomide + Dexamethasone) 11.53 months (95% CI 8.936 to 13.897) vs Pd (Pomalidomide + Dexamethasone) 6.47 months (95% CI 4.468 to 8.279)
IxazomibApprovedSmall moleculeProteasomeReliable signal
NCT02312258: Progression Free Survival (PFS) (From randomization until PD or death (up to 52 months)): Ixazomib 17.4 months (95% CI 14.78 to 20.3) vs Placebo 9.4 months (95% CI 8.51 to 11.47)
NCT02181413: Progression Free Survival (PFS) (Randomization up to End of treatment (EOT) (24 months); thereafter followed up every 4 weeks (up to 45 months)): Ixazomib Citrate 26.5 months (95% CI 23.69 to 33.81) vs Placebo 21.3 months (95% CI 17.97 to 24.67)
LenalidomideApprovedSmall moleculeCereblon E3 ubiquitin-ligase, Thalidomide AnalogReliable signal
NCT00424047: Kaplan-Meier Estimate of Time to Tumor Progression (TTP) (From randomization up to cut-off date of 03 August 2005; up to 24 months): Lenalidomide Plus Dexamethasone 52.1 weeks vs Placebo Plus Dexamethasone 20.1 weeks (95% CI 16.6 to 20.7)
NCT00056160: Time to Tumor Progression (TTP) (60 weeks (median Time To Progression of CC-5013/Dex treatment group)): CC-5013/Dex 60.1 Weeks (95% CI 41.1 to 80) vs Placebo/Dex 20.1 Weeks (95% CI 16.1 to 21.1)
LinvoseltamabApprovedMultispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
Melphalan Hydrochloride (Evomela)ApprovedSmall moleculeDNA (guanine N7 position)Weak signal
NCT03159702: Progression-free Survival (PFS) of Participants With Hematological Malignancies Undergoing Treatment. (1 year): MEL/FLU and Total-Body Irradiation (TBI) 17/43
MotixafortideApprovedPeptideCXCR4Partial signal
NCT03246529: Proportion of patients who collected at least 6 x 10^6 CD34+ cells/kg in up to 2 aphereses (central laboratory), randomized Part 2, motixafortide + filgrastim (n=80) vs placebo + filgrastim (n=42): 67.5% vs 9.5%, adjusted difference 56.8%, p < 0.0001 (stratified Cochran-Mantel-Haenszel; APHEXDA US label, section 14). CT.gov posted results for the same randomized groups give 70.0% vs 14.3%, p < 0.0001 (Cochran-Mantel-Haenszel).
NCT02639559: Number of Donors That Mobilize ≥ 2 x 10^6 CD34+ Cells/kg of Recipients Weight After a Single Injection of BL-8040 After no More Than Two Leukapheresis Collections (Arm 1 - Donors Only) (Up to Day 2): Arm 1: Donors 22/24
PlerixaforApprovedSmall moleculeCXCR4Partial signal
NCT00103662: Collection of at least 6 x 10^6 CD34+ cells/kg in 2 or fewer aphereses: plerixafor plus G-CSF 71.6% (106/148) vs placebo plus G-CSF 34.4% (53/154), P<.001 (DiPersio et al., Blood 2009).
PomalidomideApprovedSmall moleculeCereblon (CRBN)Partial signal
NCT01324947: Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria Based on Investigator Assessment (From randomization through the study follow-up phase; up to the data cut-off of 31 July 2014; Maximum time on follow-up was 141.1 weeks.): Pomalidomide 23%
NCT01311687: Progression-free Survival (PFS) - Primary Analysis (From randomization until the data cut-off date of 07 September 2012. Maximum duration of follow-up for PFS assessments was 57 weeks.): Pomalidomide Plus Low-Dose Dexamethasone 15.7 weeks (95% CI 13 to 20.1) vs High-Dose Dexamethasone 8 weeks (95% CI 7 to 9)
SelinexorApprovedSmall moleculeXPO1 (exportin-1)Partial signal
NCT03110562: SVd/Vd Arm: Progression-free Survival (PFS) as Assessed by Independent Review Committee (IRC) (From date of randomization until IRC-confirmed documented PD or death, censored date, whichever occurred first (up to 33 months)): SVd Arm: Selinexor + Bortezomib + Dexamethasone 13.93 Months vs Vd Arm: Bortezomib + Dexamethasone 9.46 Months (95% CI 8.11 to 10.78)
TalquetamabApprovedMultispecific antibodyGPRC5D x CD3not yet gradedNo reviewed efficacy summary in this indication
TeclistamabApprovedMultispecific antibodyBCMA x CD3Partial signal
NCT05083169: Primary endpoint, progression-free survival: teclistamab plus daratumumab was statistically significant and superior to DPd/DVd (J&J, 2025-10-16).
NCT04696809: Phase 2 primary endpoint ORR 76.9% (>=VGPR 76.9%, >=CR 65.4%) in 26 patients at RP2D 1.5 mg/kg; median follow-up 14.32 months
ThalidomideApprovedSmall moleculeCereblon E3 ubiquitin-ligasePartial signalFeatured results are non-efficacy only in this race
Zoledronic Acid (Zometa)ApprovedSmall moleculeFarnesyl pyrophosphate synthase (FPPS)not yet gradedNo reviewed efficacy summary in this indication
PanobinostatUS approval withdrawnSmall moleculeHDACPartial signal
NCT01023308: Progression-free survival (investigator-assessed): median 11.99 months with panobinostat + bortezomib + dexamethasone vs 8.08 months with placebo + bortezomib + dexamethasone; HR 0.63 (95% CI 0.52-0.76), p<0.0001 (Lancet Oncology 2014)
Anitocabtagene AutoleucelPhase 3Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
Arlocabtagene AutoleucelPhase 3Cell therapyGPRC5DWeak signalFeatured results are safety only in this race
AZD0120Phase 3Cell therapyBCMA / CD19not yet gradedNo reviewed efficacy summary in this indication
BCD-264Phase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
CevostamabPhase 3Multispecific antibodyFcRH5 (FcRL5) x CD3not yet gradedNo reviewed efficacy summary in this indication
CT-P44Phase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
Denosumab (Xgeva)Phase 3Monoclonal antibodyRANKLReliable signal
NCT01345019: Time to First On-study Skeletal Related Event (From randomization until the primary analysis data cut-off date of 19 July 2016 (per protocol); median time on study was 17.6 and 17.3 months in each treatment group respectively.): Denosumab 695 days vs Zoledronic Acid 730 days (95% CI 504 to 1014)
Equecabtagene AutoleucelPhase 3Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
EtentamigPhase 3Multispecific antibodyBCMA x CD3Partial signal
NCT06158841: Dual primary endpoints met: objective response rate and progression-free survival vs standard available therapies (PFS HR 0.40, P<0.0001) (AbbVie, 2026-09-03).
F182112Phase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
FelzartamabPhase 3Monoclonal antibodyCD38Partial signal
NCT03952091: Median PFS: 18·9 months felzartamab+Rd vs 10·4 months Rd (hazard ratio 0·62; p=0·0035)
Gamgertamig (CM336)Phase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
HLX15Phase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
IBI3003Phase 3Multispecific antibodyGPRC5D x BCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
InobrodibPhase 3Small moleculeCBP/p300 (bromodomain)not yet gradedNo reviewed efficacy summary in this indication
LumrotatugPhase 3Monoclonal antibodyCD38Weak signal
NCT04818372: CM313 phase 1 dose-escalation/expansion (NCT04818372, anti-CD38 mAb, R/R multiple myeloma + marginal zone lymphoma): grade>=3 TEAEs 15/34 (44.1%), no DLTs; ORR 34.5% among 29 evaluable RRMM patients; median PFS 132 days.
MezigdomidePhase 3Small moleculeCereblon E3 ubiquitin-ligasePartial signal
NCT05552976: Primary endpoint, progression-free survival: statistically significant and clinically meaningful improvement vs carfilzomib and dexamethasone (Bristol Myers Squibb, 2026-03-09).
PlitidepsinPhase 3Small moleculeeEF1A2 (eukaryotic translation elongation factor 1-alpha 2)Partial signal
NCT01102426: Progression Free Survival (PFS) as Per Intention-to-treat (ITT) (From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years): Plitidepsin+Dexamethasone 2.6 months (95% CI 1.9 to 3) vs Dexamethasone 1.7 months (95% CI 1.1 to 2)
QL2109Phase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
QLS32015Phase 3Multispecific antibodyGPRC5D x CD3not yet gradedNo reviewed efficacy summary in this indication
QLS4131Phase 3Multispecific antibodyGPRC5D x BCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
RamantamigPhase 3Multispecific antibodyGPRC5D x BCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
SanritatugPhase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
SCTC21CPhase 3Biologic (subtype unspecified)CD38not yet gradedNo reviewed efficacy summary in this indication
TorutamigPhase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
TQB2934Phase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
Velinotamig (GR1803)Phase 3Multispecific antibodyBCMA x CD3Weak signalNo reviewed efficacy summary in this indication
VenetoclaxPhase 3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
Burixafor (TG-0054)Phase 2Small moleculeCXCR4Weak signal
NCT01458288: Number of Patients Achieving the CD34+ Hematopoietic Stem Cell (HSC) Mobilization Target of ≧2.5×1000000 Cells/kg (1 week): TG-0054 (3.14 mg/kg) 7/7 | TG-0054 (3.14 mg/kg)+G-CSF 5/5
NCT01018979: Primary mobilization success: 2/4 patients in the TG-0054 2.24 mg/kg group (MM 1, NHL 1) vs 1/3 patients in the 3.14 mg/kg group (MM 1); no p-value or confidence interval reported.
CemsidomidePhase 2Small moleculeCereblon E3 ubiquitin-ligasenot yet gradedNo reviewed efficacy summary in this indication
Hrain Anti-BCMA CAR-TPhase 2Cell therapyBCMAWeak signalFeatured results are safety only in this race
HRC0202Phase 2Cell therapyBCMAWeak signalFeatured results are safety only in this race
Iopofosine I-131Phase 2Radiopharmaceuticalphospholipid ether (selective lipid raftWeak signal
NCT02278315: The phase 1 dose-escalation and safety study enrolled 31 patients with relapsed or refractory multiple myeloma who had received a median of four prior lines of therapy. It established 31.25 mCi/m2 as the maximum tolerated single dose and identified 20 mCi/m2 administered twice, one week apart, as the highest evaluated fractionated dose regimen.
LMY-920Phase 2Cell therapyBCMA / TACInot yet gradedNo reviewed efficacy summary in this indication
RAPA-201Phase 2Cell therapyRapamycin-resistant autologous T-cell therapyWeak signal
NCT04176380: Overall response rate: 9/14 patients (64%) achieved disease remission (IMWG criteria) - 8 partial responses, 1 stringent complete response.
YKST02Phase 2Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
AZD4045Phase 1/2Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
BCMA CAR-NK (Shenzhen Pregene Biopharma)Phase 1/2Cell therapyBCMAWeak signalNo reviewed efficacy summary in this indication
BCMA-Targeted Prime CAR-T Cells (Chongqing Precision Biotech)Phase 1/2Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
BelantamabPhase 1/2Monoclonal antibodyBCMAnot yet gradedNo reviewed efficacy summary in this indication
PirtobrutinibPhase 1Small moleculeBTKnot yet gradedNo reviewed efficacy summary in this indication
TQB3602Phase 1Small moleculeProteasomeWeak signal
NCT04275583: Twenty-five patients with relapsed/refractory multiple myeloma who had relapsed or failed at least 2 lines of therapy were enrolled in the dose-escalation phase. Two patients in the 7.0 mg dose group developed dose-limiting toxicities, giving a maximum tolerated dose of 6.0 mg. Any-grade adverse events occurred in 24 (96.0%) patients and grade >=3 adverse events in 13 (52.0%). Among 22 response-evaluable patients, 63.7% achieved stable disease or better.

Large race: only the 64 furthest-along competitors are listed; 103 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(88 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Bortezomib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (12)
November 2026 (2)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2026-11 · NCT06505369 · CT.gov ↗
What to watch
Phase 1/2Multiple MyelomaActive not recruiting
Est. primary completion 2026-11-30 · NCT03989414 · CT.gov ↗
What to watch
December 2026 (10)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2026-12 · NCT02718833 · CT.gov ↗
What to watch
Phase 2Metastatic Castration-resistant Prostate CancerActive not recruiting
Est. primary completion 2026-12 · NCT06029998 · CT.gov ↗
What to watch
Phase 2Systemic AmyloidosisRecruiting
Est. primary completion 2026-12 · NCT06342466 · CT.gov ↗
What to watch
Phase 2Plasma Cell LeukemiaRecruiting
Est. primary completion 2026-12-01 · NCT05979363 · CT.gov ↗
What to watch
Phase 2Mantle Cell LymphomaNot yet recruiting
Est. primary completion 2026-12-01 · NCT06656221 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2026-12-28 · NCT03729804 · CT.gov ↗
What to watch
Phase 1/2GlioblastomaRecruiting
Est. primary completion 2026-12-30 · NCT03643549 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2026-12-31 · NCT01863550 · CT.gov ↗
What to watch
Phase 1Breast CancerRecruiting
Est. primary completion 2026-12-31 · NCT04265872 · CT.gov ↗
What to watch
Phase 1/2Multiple MyelomaActive not recruiting
Est. primary completion 2026-12-31 · NCT05514990 · CT.gov ↗
What to watch
2027 (33)
January 2027 (2)
Phase 4Multiple MyelomaActive not recruiting
Est. primary completion 2027-01-03 · NCT03829371 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2027-01-10 · NCT05519085 · CT.gov ↗
What to watch
February 2027 (3)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-02-01 · NCT04268498 · CT.gov ↗
What to watch
Phase 2Sickle Cell Disease, Thalassemia, Beta, ThalassemiaRecruiting
Est. primary completion 2027-02-09 · NCT05736419 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-02-26 · NCT04133636 · CT.gov ↗
What to watch
March 2027 (3)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-03 · NCT04166565 · CT.gov ↗
What to watch
Early phase / not applicableMultiple MylomaNot yet recruiting
Est. primary completion 2027-03-25 · NCT06876298 · CT.gov ↗
What to watch
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2027-03-31 · NCT04068597 · CT.gov ↗
What to watch
April 2027 (3)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2027-04 · NCT02343042 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2027-04 · NCT05558319 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2027-04-05 · NCT03319667 · CT.gov ↗
What to watch
May 2027 (1)
Phase 1AL AmyloidosisActive not recruiting
Est. primary completion 2027-05-06 · NCT04754945 · CT.gov ↗
What to watch
July 2027 (1)
Phase 2Plasmablastic LymphomaRecruiting
Est. primary completion 2027-07-01 · NCT04915248 · CT.gov ↗
What to watch
August 2027 (3)
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2027-08 · NCT00572169 · CT.gov ↗
What to watch
Phase 2/3Multiple MyelomaRecruiting
Est. primary completion 2027-08 · NCT05665140 · CT.gov ↗
What to watch
Phase 2Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia, Recurrent Burkitt Lymphoma …Recruiting
Est. primary completion 2027-08-01 · NCT03136146 · CT.gov ↗
What to watch
October 2027 (5)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-10 · NCT00869232 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-10 · NCT03004287 · CT.gov ↗
What to watch
Phase 1/2Graft Vs Host DiseaseRecruiting
Est. primary completion 2027-10 · NCT06681922 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaNot yet recruiting
Est. primary completion 2027-10-09 · NCT07789522 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-10-30 · NCT03763162 · CT.gov ↗
What to watch
November 2027 (2)
Phase 1/2Graft-versus-host DiseaseRecruiting
Est. primary completion 2027-11 · NCT05289167 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2027-11 · NCT07018050 · CT.gov ↗
What to watch
December 2027 (10)
Phase 2MyelomaActive not recruiting
Est. primary completion 2027-12 · NCT00871013 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2027-12 · NCT06158841 · CT.gov ↗
What to watch
Phase 2T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma, Mixed Phenotype Acute LeukemiaRecruiting
Est. primary completion 2027-12 · NCT06390319 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2027-12 · NCT07297329 · CT.gov ↗
What to watch
Phase 3AmyloidosisRecruiting
Est. primary completion 2027-12 · NCT07388602 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2027-12-20 · NCT04775550 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid Leukemia, TP53Recruiting
Est. primary completion 2027-12-30 · NCT07008638 · CT.gov ↗
What to watch
Phase 2Acute Lymphoblastic Leukemia (ALL)Recruiting
Est. primary completion 2027-12-31 · NCT03590171 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2027-12-31 · NCT04566328 · CT.gov ↗
What to watch
Phase 2Relapsed/Refractory Immune ThrombocytopeniaRecruiting
Est. primary completion 2027-12-31 · NCT05599880 · CT.gov ↗
What to watch
2028 (14)
January 2028 (2)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-01 · NCT04414475 · CT.gov ↗
What to watch
Phase 2Hematological MalignancyRecruiting
Est. primary completion 2028-01-01 · NCT03850366 · CT.gov ↗
What to watch
March 2028 (4)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-03 · NCT05272826 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2028-03-25 · NCT05137054 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-03-31 · NCT07045909 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2028-03-31 · NCT07341867 · CT.gov ↗
What to watch
April 2028 (1)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2028-04-26 · NCT06353022 · CT.gov ↗
What to watch
June 2028 (1)
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2028-06 · NCT03617731 · CT.gov ↗
What to watch
July 2028 (2)
Phase 4Multiple MyelomaNot yet recruiting
Est. primary completion 2028-07 · NCT07334535 · CT.gov ↗
What to watch
Phase 3Acute Lymphoblastic Leukemia, PediatricRecruiting
Est. primary completion 2028-07-14 · NCT03643276 · CT.gov ↗
What to watch
August 2028 (1)
Phase 2Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed RemissionRecruiting
Est. primary completion 2028-08 · NCT06034561 · CT.gov ↗
What to watch
September 2028 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-09-15 · NCT05695508 · CT.gov ↗
What to watch
October 2028 (1)
Phase 2Lymphoproliferative Disorder, HHV-8, Malignancy, HIVActive not recruiting
Est. primary completion 2028-10-01 · NCT00092222 · CT.gov ↗
What to watch
December 2028 (1)
Phase 1/2Lymphoblastic LeukemiaRecruiting
Est. primary completion 2028-12 · NCT05848687 · CT.gov ↗
What to watch
2029 (12)
January 2029 (3)
Phase 3Hematological Malignancies, Platelet Transfusion Refractoriness (PTR), HLA AntibodiesNot yet recruiting
Est. primary completion 2029-01-01 · NCT07635511 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2029-01-11 · NCT07085728 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2029-01-11 · NCT07764978 · CT.gov ↗
What to watch
February 2029 (2)
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2029-02-14 · NCT04923893 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaNot yet recruiting
Est. primary completion 2029-02-28 · NCT07614360 · CT.gov ↗
What to watch
May 2029 (2)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2029-05-05 · NCT07891923 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2029-05-21 · NCT07222761 · CT.gov ↗
What to watch
June 2029 (1)
Phase 2Plasma Cell Leukemia (PCL)Recruiting
Est. primary completion 2029-06-30 · NCT07652905 · CT.gov ↗
What to watch
July 2029 (1)
Phase 1/2Multiple MyelomaNot yet recruiting
Est. primary completion 2029-07-01 · NCT07601100 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2Waldenstrom MacroglobulinemiaNot yet recruiting
Est. primary completion 2029-08-01 · NCT07464210 · CT.gov ↗
What to watch
December 2029 (2)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2029-12-01 · NCT04240054 · CT.gov ↗
What to watch
Phase 1T-cell Acute Lymphoblastic Leukemia, LymphomaRecruiting
Est. primary completion 2029-12-31 · NCT07513129 · CT.gov ↗
What to watch
2030 (5)
July 2030 (2)
Phase 1/2GVHD - Graft-Versus-Host DiseaseRecruiting
Est. primary completion 2030-07-01 · NCT07675174 · CT.gov ↗
What to watch
Phase 3AL AmyloidosisRecruiting
Est. primary completion 2030-07-29 · NCT06022939 · CT.gov ↗
What to watch
August 2030 (1)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2030-08-30 · NCT07227311 · CT.gov ↗
What to watch
September 2030 (1)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2030-09-02 · NCT06577025 · CT.gov ↗
What to watch
December 2030 (1)
Phase 2Multiple MyelomaNot yet recruiting
Est. primary completion 2030-12-01 · NCT07247097 · CT.gov ↗
What to watch
2031 (3)
May 2031 (1)
Phase 2Multiple MyelomaActive not recruiting
Est. primary completion 2031-05 · NCT03314181 · CT.gov ↗
What to watch
August 2031 (1)
Phase 1Multiple MyelomaNot yet recruiting
Est. primary completion 2031-08-22 · NCT07609706 · CT.gov ↗
What to watch
November 2031 (1)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2031-11 · NCT07285239 · CT.gov ↗
What to watch
2033 (4)
January 2033 (1)
Phase 2AmyloidosisRecruiting
Est. primary completion 2033-01-12 · NCT07224672 · CT.gov ↗
What to watch
June 2033 (1)
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2033-06 · NCT05257083 · CT.gov ↗
What to watch
August 2033 (1)
Phase 2/3Multiple MyelomaNot yet recruiting
Est. primary completion 2033-08-01 · NCT07887984 · CT.gov ↗
What to watch
October 2033 (1)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2033-10-01 · NCT07624513 · CT.gov ↗
What to watch
2035 (1)
September 2035 (1)
Phase 2/3Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma, Stage IV T Lymphoblastic Leukemia/Lymphoma …Not yet recruiting
Est. primary completion 2035-09-01 · NCT07072585 · CT.gov ↗
What to watch
2036 (2)
May 2036 (1)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2036-05 · NCT06918002 · CT.gov ↗
What to watch
September 2036 (1)
Phase 1/2Multiple MyelomaNot yet recruiting
Est. primary completion 2036-09-30 · NCT07600151 · CT.gov ↗
What to watch
2039 (1)
March 2039 (1)
Phase 3Multiple MyelomaNot yet recruiting
Est. primary completion 2039-03 · NCT07903506 · CT.gov ↗
What to watch
2042 (1)
February 2042 (1)
Phase 3Multiple MyelomaNot yet recruiting
Est. primary completion 2042-02 · NCT07887672 · CT.gov ↗
What to watch

See the full readout calendar ↗